Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group, two of China’s largest drug makers, are expected to report significantly improved profits, buoyed by novel drug roll-outs and revenue from technology licensing.
On August 21, Hengrui, China’s largest drug maker by market value, is expected to say its net profit for the first half rose 40 per cent from a year earlier to 4.1 billion yuan (US$570.8 million), with revenue up 9 per cent to 15.7 billion yuan, according to analysts’ consensus estimates from Bloomberg. For all of 2025, the company’s profit is expected to improve 28 per cent to 8.1 billion yuan.
“The launches of these innovative drugs will further improve Hengrui’s revenue structure and shrink the role of generic drugs in its business,” Huayuan Securities analyst Liu Chuang said in a July 29 report.
According to a recent report from Guotai Haitong Securities, generics accounted for 43 per cent of Hengrui’s revenue last year, down from 62 per cent in 2022. That figure was expected to fall to 23 per cent in 2027.
